How to buy NexImmune stock | $18.58

NexImmune, Inc is a biotechnology business based in the US. NexImmune shares (NEXI) are listed on the NASDAQ and all prices are listed in US Dollars. NexImmune employs 44 staff and has a market cap (total outstanding shares value) of 0.00.

NexImmune stock price (NASDAQ: NEXI)

Use our graph to track the performance of NEXI stocks over time.

NexImmune shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$18.58
52-week range	$11.50 - $28.00
50-day moving average	$15.62
200-day moving average	$18.81
Wall St. target price	$33.33
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy NexImmune shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy NexImmune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of NexImmune, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NexImmune price performance over time

Historical closes compared with the close of $18.58 from 2021-05-28

1 week (2021-07-18)	N/A
1 month (2021-06-29)	13.64%
3 months (2021-04-29)	-4.82%
6 months (2021-01-25)	N/A

1 year (2020-07-25)	N/A
2 years (2019-07-25)	N/A
3 years (2018-07-25)	N/A
5 years (2016-07-25)	N/A

NexImmune financials

Gross profit TTM	$0
Return on assets TTM	-139.15%
Return on equity TTM	0%
Profit margin	0%
Book value	$5.34
Market capitalisation	$270.5 million

TTM: trailing 12 months

Shorting NexImmune shares

There are currently 343,225 NexImmune shares held short by investors – that's known as NexImmune's "short interest". This figure is 23.2% up from 278,499 last month.

There are a few different ways that this level of interest in shorting NexImmune shares can be evaluated.

NexImmune's "short interest ratio" (SIR)

NexImmune's "short interest ratio" (SIR) is the quantity of NexImmune shares currently shorted divided by the average quantity of NexImmune shares traded daily (recently around 39496.547756041). NexImmune's SIR currently stands at 8.69. In other words for every 100,000 NexImmune shares traded daily on the market, roughly 8690 shares are currently held short.

To gain some more context, you can compare NexImmune's short interest ratio against those of similar companies.

• HOOKIPA Pharma (HOOK.US): 3.26
• Caladrius Biosciences (CLBS.US): 2.38
• Capricor Therapeutics (CAPR.US): 3.35

However NexImmune's short interest can also be evaluated against the total number of NexImmune shares, or, against the total number of tradable NexImmune shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NexImmune's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 NexImmune shares in existence, roughly 20 shares are currently held short) or 0.0243% of the tradable shares (for every 100,000 tradable NexImmune shares, roughly 24 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NexImmune.

Find out more about how you can short NexImmune stock.

NexImmune share dividends

We're not expecting NexImmune to pay a dividend over the next 12 months.

NexImmune overview

NexImmune, Inc. , a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; and NEXI-002, an autologous cell therapy, which is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. .

Frequently asked questions

What percentage of NexImmune is owned by insiders or institutions?
Currently 11.986% of NexImmune shares are held by insiders and 43.117% by institutions. How many people work for NexImmune?
Latest data suggests 44 work at NexImmune. When does the fiscal year end for NexImmune?
NexImmune's fiscal year ends in December. Where is NexImmune based?
NexImmune's address is: 9119 Gaither Road, Gaithersburg, MD, United States, 20877